-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $108

Benzinga·12/17/2025 17:54:17
Listen to the news
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $88 to $108.